Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Relapsed Acute Myeloid Leukemia: early-phase trial registry
5 of 6 indexed Relapsed Acute Myeloid Leukemia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 5 currently recruiting · #2,866 of 28,707 conditions by registered trial count
Relapsed Acute Myeloid Leukemia: 6 US clinical trials tracked, 5 recruiting.
Relapsed Acute Myeloid Leukemia is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Foghorn Therapeutics, running 1 of these trials.
Enrollment posture brief
Registry condition relapsed-acute-myeloid-leukemia
OPEN 5 | RECR 83% | LATE 0 | EARLY 6 | RANK #2866 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Alcoholic Hepatitis (83% recruiting · 6 trials)
Relapsed Acute Myeloid Leukemia lists 5 open slots (83% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Relapsed Acute Myeloid Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Relapsed Acute Myeloid Leukemia is recruiting above its size-band peers.
5 of 6 indexed trials (83.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Relapsed Acute Myeloid Leukemia research.
Foghorn Therapeutics accounts for 1 of 6 trials (16.7%). 6 distinct sponsors appear on at least one study for this condition label.
-
Most Relapsed Acute Myeloid Leukemia trials plan to enrol fewer than 100 people.
Median target enrolment is 36 among the 6 trials that report a genuine target (sentinel values excluded). 5 of those (83.3%) plan for fewer than 100 participants.
-
Relapsed Acute Myeloid Leukemia research is mostly interventional.
6 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
University of Washington
NCT04797767
Imetelstat Combinations in Relapsed AML
Douglas Tremblay
NCT07320235
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
St. Jude Children's Research Hospital
NCT06177067
Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML
Stanford University
NCT06561152
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia
Memorial Sloan Kettering Cancer Center
NCT06017258
FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies
Foghorn Therapeutics
NCT04891757
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
Top Sponsors
Named interventions
Most-linked intervention names on Relapsed Acute Myeloid Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Relapsed Acute Myeloid Leukemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Relapsed Acute Myeloid Leukemia page
6 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Relapsed Acute Myeloid Leukemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Foghorn Therapeutics sponsors the most Relapsed Acute Myeloid Leukemia trials on record, review their full trial history before evaluating a specific study. See Foghorn Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Relapsed Acute Myeloid Leukemia condition card totals 6 registered trials; most-linked intervention Cytarabine; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.